Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01866410 | Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | May 16, 2019 | clinicaltrials |
| NCT03059797 | Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202) | completed | Phase 2 | 120 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 16, 2019 |
| NCT00387465 | Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | May 9, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT02176369 | Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial(ONC-MANILA12) | completed | Phase 2 | 120 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT01173523 | Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 25 | David M. Jackman, MDOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02054052 | Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer | completed | Phase 2 | 22 | Haihong Yang, MD, Pricipal investigatorOTHER | 1 | Mar 29, 2019 | clinicaltrials |
| NCT01685138 | LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | completed | Phase 2 | 124 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 26, 2019 | clinicaltrials |
| NCT00614822 | Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer(H3E-US-X072) | completed | Phase 2 | 50 | Christiana Care Health ServicesOTHER | 0 | Mar 20, 2019 | clinicaltrials |
| NCT01949701 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01950156 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02340208 | A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 | completed | Phase 1 / Phase 2 | 76 | Helix BioPharma CorporationINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01487265 | Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT00459342 | Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT02040870 | LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | completed | Phase 1 / Phase 2 | 103 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT03239171 | Bioinformation Therapy for Lung Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT01415011 | Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients(TIMELY) | completed | Phase 2 | 39 | University College, LondonOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00918203 | A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 137 | Eli Lilly and CompanyINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT01465802 | Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO(ARCHER 1042) | completed | Phase 2 | 236 | PfizerINDUSTRY | 2 | Jan 9, 2019 | clinicaltrials |
| NCT00125359 | Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer | completed | Phase 2 | 42 | Konstantin DragnevOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01846416 | A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] | completed | Phase 2 | 138 | Genentech, Inc.INDUSTRY | 5 | Jan 8, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT00385996 | Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer | completed | Phase 2 | 22 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 28, 2018 | clinicaltrials |
| NCT01497873 | A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer | completed | Phase 2 | 164 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 27, 2018 | clinicaltrials |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 178 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Dec 27, 2018 | clinicaltrials |
| NCT00567359 | Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR | completed | Phase 2 | 100 | Massachusetts General HospitalOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT02289456 | Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2(AboundPS2) | completed | Phase 2 | 40 | CelgeneINDUSTRY | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02655913 | Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer(VCONSCLC) | completed | Phase 1 / Phase 2 | 97 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Nov 30, 2018 | clinicaltrials |
| NCT02200081 | Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC(IMPULSE) | completed | Phase 2 | 103 | Mologen AGINDUSTRY | 4 | Nov 15, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT01260181 | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 30 | Hoffmann-La RocheINDUSTRY | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00363766 | Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 52 | Eli Lilly and CompanyINDUSTRY | 2 | Oct 19, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT00864721 | Sunitinib Non Small Cell Lung Cancer Patients Over 70 | completed | Phase 2 | 63 | US Oncology ResearchINDUSTRY | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02875340 | A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 8 | ValiSeek LimitedINDUSTRY | 0 | Oct 15, 2018 | clinicaltrials |
| NCT00188279 | Minimum Dose Computed Tomography of the Thorax for Follow-up in Patients With Resected Lung Carcinoma | completed | Phase 2 | 311 | University Health Network, TorontoOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT00994097 | NGR-hTNF in Combination With Standard Chemotherapy to Treat Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 121 | AGC Biologics S.p.A.INDUSTRY | 1 | Sep 27, 2018 | clinicaltrials |
| NCT00252382 | Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC | completed | Phase 2 | 31 | Sunesis PharmaceuticalsINDUSTRY | 1 | Sep 24, 2018 | clinicaltrials |
| NCT01174563 | A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy | completed | Phase 2 | 60 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01310036 | A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 4 | Sep 12, 2018 | clinicaltrials |
| NCT00638937 | AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2018 | clinicaltrials |
| NCT02123849 | Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01871805 | A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 134 | Hoffmann-La RocheINDUSTRY | 2 | Aug 21, 2018 | clinicaltrials |
| NCT01207063 | Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 40 | Maastricht Radiation OncologyOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01901653 | Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 82 | StemcentrxINDUSTRY | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00654420 | A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007) | completed | Phase 2 | 95 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT00298896 | Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer | completed | Phase 2 | 55 | Sunesis PharmaceuticalsINDUSTRY | 2 | Jul 26, 2018 | clinicaltrials |
| NCT00098956 | 7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2018 | clinicaltrials |
| NCT00527735 | Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 334 | Bristol-Myers SquibbINDUSTRY | 8 | Jul 18, 2018 | clinicaltrials |
Data updated 23 days agoSource updated May 16, 2019source: clinicaltrials